公开(公告)号：EP4420673A2

公开(公告)日：2024-08-28

申请号：EP24169078.3

申请日：2020-08-03

申请人： Bioversys AG

发明人： DALE, Glenn, E. ,  LOCIURO, Sergio ,  KEMMER, Christian ,  TREBOSC, Vincent ,  GITZINGER, Marc

IPC分类号： A61K38/12

CPC分类号： A61K31/438 ,  A61P31/04 ,  A61K9/0019 ,  A61K38/12 ,  A61K31/546 ,  Y02A50/30

摘要： The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

公开(公告)号：EP4393491A2

公开(公告)日：2024-07-03

申请号：EP24163449.2

申请日：2015-05-15

申请人： Insmed Incorporated

发明人： EAGLE, Gina ,  GUPTA, Renu

IPC分类号： A61K31/4709

CPC分类号： A61K9/127 ,  A61P31/04 ,  A61K31/7036 ,  A61K9/0078 ,  A61K31/133 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052

摘要： Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

公开(公告)号：EP3377473B1

公开(公告)日：2024-06-19

申请号：EP16840309.5

申请日：2016-11-21

IPC分类号： C07D245/04 ,  A61K31/395 ,  A61P31/04

CPC分类号： C07K5/0202 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K45/06 ,  A61K31/395 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/43 ,  A61K31/431 ,  A61K31/496 ,  A61K31/545 ,  A61K31/546 ,  C07K5/0812 ,  C07K5/1008 ,  C07K5/1019 ,  C07K7/06 ,  C07K7/08 ,  C07K5/1013 ,  C07K5/1021 ,  C07K9/008 ,  C07K5/1024 ,  C07K5/0815 ,  A61P31/04 ,  C07D245/04 ,  Y02A50/30

公开(公告)号：EP3484469B1

公开(公告)日：2024-05-22

申请号：EP17827133.4

申请日：2017-07-13

IPC分类号： A61K31/352 ,  A61K31/16 ,  A61K31/65 ,  A61K31/7036 ,  A61P31/04 ,  A61K31/065 ,  A61K31/353 ,  A61K31/43 ,  A61K31/546

CPC分类号： A61K31/16 ,  A61K31/352 ,  A61K31/43 ,  A61K31/546 ,  A61K31/7036 ,  A61P31/04 ,  A61K31/065 ,  A61K31/353 ,  Y02A50/30

公开(公告)号：EP2603514B1

公开(公告)日：2018-07-18

申请号：EP11816882.2

申请日：2011-08-08

申请人： Rempex Pharmaceuticals, Inc.

发明人： HIRST, Gavin ,  REDDY, Raja ,  HECKER, Scott ,  TOTROV, Maxim ,  GRIFFITH, David, C. ,  RODNY, Olga ,  DUDLEY, Michael, N. ,  BOYER, Serge

IPC分类号： C07F5/02 ,  A61K31/69 ,  A61P31/04

CPC分类号： A61K31/69 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/546 ,  A61K45/06 ,  C07F5/025 ,  Y02A50/401 ,  Y02A50/406 ,  Y02A50/47 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/483 ,  A61K2300/00

摘要： Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

公开(公告)号：EP2596783B1

公开(公告)日：2018-06-06

申请号：EP12186239.5

申请日：2012-09-27

申请人： Limonov, Viktor Lvovich

发明人： Limonov, Viktor Lvovich ,  Gaidul, Konstantin Valentinovich ,  Dushkin, Aleksandr Valerevich

IPC分类号： A61K9/00 ,  A61K9/08

CPC分类号： A61K33/14 ,  A61K9/0019 ,  A61K9/14 ,  A61K9/143 ,  A61K9/145 ,  A61K31/407 ,  A61K31/506 ,  A61K31/546 ,  A61K31/7036 ,  A61K31/7052 ,  A61K38/14 ,  A61K47/02 ,  A61K47/26 ,  Y02A50/473

摘要： The present invention relates to pharmacology, medicine, veterinary science and pharmaceutical industry, namely to pharmaceutical compositions for the preparation of infusion solutions of antimicrobial preparations potentiating the therapeutic efficacy of antimicrobial medicaments, during the process of preparing solutions thereof immediately before carrying out intravenous infusions and the process of producing original composite pharmaceutical ingredients. The claimed pharmaceutical compositions for the preparation of injection solutions of all the tested antimicrobial preparations comprising the finely dispersed powder of nanostructured colloidal silica, reliably increase their therapeutic efficacy when treating generalised sepsis in test animals, provoked by Staphylococcus aureus, Escherichia coli, Pseudo-monas aeruginosa and Candida albicans. The claimed pharmaceutical compositions for the preparation of antibacterial and antifungal preparations solutions for intravenous infusions (NaCl:Colloidal silica and Dextrose:Colloidal silica) have a significant clinically sginificant potentiating action on their therapeutic potential when treating inflammatory infectious disease, in comparison with traditional solvents (prototypes of the invention).

公开(公告)号：EP3319609A1

公开(公告)日：2018-05-16

申请号：EP16822054.9

申请日：2016-07-08

申请人： Washington University ,  University of Notre Dame du Lac

发明人： DANTAS, Gautam ,  GONZALES, Patrick ,  FORSBERG, Kevin ,  PESESKY, Mitchell ,  CHANG, Mayland ,  MOBASHERY, Shahriar

IPC分类号： A61K31/546 ,  A61K31/407 ,  C07D477/12

CPC分类号： A61K31/407 ,  A61K31/424 ,  A61K31/43 ,  A61K31/431 ,  A61K31/496 ,  A61K31/546 ,  A61K45/06 ,  A61P31/04 ,  A61K2300/00

摘要： The present disclosure encompasses antibacterial compositions and methods of treating bacterial infections caused by resistant bacteria.

公开(公告)号：EP3139918A4

公开(公告)日：2018-05-09

申请号：EP15789928

申请日：2015-05-04

申请人： MERCK SHARP & DOHME

发明人： TANG HAIFENG ,  YANG SHU-WEI ,  MANDAL MIHIR ,  SU JING ,  LI GUOQING ,  PAN WEIDONG ,  TANG HAIQUN ,  DEJESUS REYNALDA ,  PAN JIANPING ,  HAGMANN WILLIAM ,  DING FA-XIANG ,  XIAO LI ,  PASTERNAK ALEXANDER ,  HUANG YUHUA ,  DONG SHUZHI ,  YANG DEXI

IPC分类号： A61K31/41 ,  A61K31/192 ,  C07D257/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D405/10 ,  C07D409/06 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04

CPC分类号： A61K31/546 ,  A61K31/407 ,  A61K31/41 ,  A61K31/427 ,  A61K31/43 ,  A61K31/44 ,  A61K31/496 ,  A61K45/06 ,  A61K2121/00 ,  C07D257/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D405/10 ,  C07D409/06 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  A61K2300/00

摘要： The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

公开(公告)号：EP3313828A1

公开(公告)日：2018-05-02

申请号：EP16815358.3

申请日：2016-06-24

申请人： Merck Sharp & Dohme Corp.

发明人： BENNETT, Frank ,  JIANG, Jinlong ,  PASTERNAK, Alexander ,  DONG, Shuzhi ,  GU, Xin ,  SCOTT, Jack, D. ,  TANG, Haiqun ,  ZHAO, Zhiqiang ,  HUANG, Yuhua ,  HUNTER, David ,  YANG, Dexi ,  YOUNG, Katherine ,  XIAO, Li ,  ZHANG, Zhibo ,  FU, Jianmin ,  BAI, Yunfeng ,  ZHENG, Zhixiang ,  ZHANG, Xu

IPC分类号： C07D257/02 ,  C07D257/04 ,  A61K31/41 ,  A61K31/395

CPC分类号： C07D403/10 ,  A61K31/198 ,  A61K31/407 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/421 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/431 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/546 ,  A61K45/06 ,  A61P31/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  C07D453/02 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D493/04 ,  C07D493/08 ,  C07D495/08

摘要： The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X 2 and R1are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

公开(公告)号：EP3313377A1

公开(公告)日：2018-05-02

申请号：EP16732720.4

申请日：2016-06-23

申请人： Lamellar Biomedical Limited

发明人： MCLEAN, Alec ,  HOWARD, Lynsey ,  KADIOGLU, Aras ,  WINSTANLEY, Craig

IPC分类号： A61K9/127 ,  A61K45/06

CPC分类号： A61K35/12 ,  A61K9/127 ,  A61K31/047 ,  A61K31/407 ,  A61K31/427 ,  A61K31/496 ,  A61K31/546 ,  A61K31/685 ,  A61K31/7036 ,  A61K31/7048 ,  A61K45/06 ,  A61K2300/00 ,  A61P31/04

摘要： Biofilm production, which provides microbes with a multi-layered structured community attached to a surface and encased within a matrix of exopolymeric material, is associated with up-regulated virulence of infection and can limit the immune system response and/or the effectiveness of therapeutic agents. The use of lamellar bodies to modulate quorum sensing to inhibit or reduce biofilm production and for treatment of microbial infections is provided.